The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Structurally Modified Analogues of Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) As Future Antidiabetic Agents
Abstract
Glucagon-like peptide-1(7-36)amide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are gastrointestinal insulin-releasing hormones involved in the regulation of postprandial nutrient homeostasis. These two incretin hormones are glucose-dependent stimulators of pancreatic beta-cell function, exhibiting a spectrum of secondary extrapancreatic activities, which favour the efficient control of blood glucose homeostasis. Such actions of GLP-1 and GIP have generated considerable interest in their possible exploitation as novel agents for the treatment of type 2 diabetes. Despite the many attributes of GLP-1 and GIP as possible future antidiabetic agents, their rapid degradation in the circulation by dipeptidyl peptidase IV (DPP IV) to inactive truncated forms GLP-1(9-36)amide and GIP(3-42), severely limits their therapeutic usefulness. This review will consider recent developments in the design and effectiveness of synthetic DPP IV-resistant analogues of GLP-1 and GIP. Consideration will be given to the effects of N-terminal modification and amino acid substitution of GLP-1 and GIP either side of the DPP IV cleavage site on (i) susceptibility to enzymatic degradation, (ii) binding to native hormone receptor, (iii) ability to elevate intracellular cyclic AMP, (iv) potency as insulin secretagogues, and (v) antihyperglycaemic activity in type 2 diabetes. It will be shown that structural modification can produce a varied set of biological activities, ranging from more efficacious analogues to those which antagonise the activity of the native hormone. The antidiabetic properties of the best GLP-1 and GIP analogues indeed promise to provide the basis for novel, effective and long-acting drugs for type 2 diabetes therapy. This approach is currently being pursued actively by the pharmaceutical industry.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“their application in T2DM treatment focuses on modified analogues320, 321, 322, 323, 324, 325 or receptor agonists, including the well-known, short-acting exenatide.326, 327, 328”
From Pancreatic regulation of glucose homeostasis. (2016) · cites this paper as [320]
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
Mentlein, R. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00089-0 · Cited by 1,272
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 3×
“These recent observations add to a growing body of evidence, which links GIP to fat deposition, obesity and glucose intolerance [54, 98-100].”
BackgroundDrucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · cited 2×
“Furthermore, the ability of both GLP-1 and GIP to stimulate insulin gene transcription and increase pancreatic beta-cell mass [3, 5, 6, 26, 29], may compensate for the dysregulation of insulin secretion synonymous with type 2 diabetes.”
BackgroundMojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
STIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Cited by
Pancreatic regulation of glucose homeostasis.
Röder, P. V., Wu, B., Liu, Y., & Han, W. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.6 · Cited by 985
Use of Alcalase in the production of bioactive peptides: A review
Tacias-Pascacio, V. G., Morellon-Sterling, R., Siar, E.-H., Tavano, O., Berenguer-Murcia, Á., & Fernandez-Lafuente, R. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.10.060 · Cited by 407
Green, B. D., Flatt, P. R., & Bailey, C. J. (2006) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2006.024 · Cited by 223
“Other antidiabetic actions of the incretin hormones are summarised in table 1 and detailed elsewhere.(4,7) Most noteworthy are the inhibition of glucagon secretion, induction of satiety, tendency for weight loss and the reduced rate of gastric emptying(20) associated with GLP-1.”
BackgroundSelf-citationIncretin-Based Therapies in Type 2 Diabetes Mellitus
Chia, C. W., & Egan, J. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2109 · Cited by 223
Harnedy, P. A., O’Keeffe, M. B., & FitzGerald, R. J. (2015) · Food Chemistry · doi:10.1016/j.foodchem.2014.09.083 · Cited by 201
Metadata
- Authors
- Green, B., Gault, V., O'Harte, F., & Flatt, P.
- Affiliations
- University of Ulster (GB)
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2004-11-01
- Volume
- 10
- Issue
- 29
- Pages
- 3651-3662
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2118100404
- Cited by
- 111
- References
- 116
- Citations by year
- 2025: 1 · 2024: 5 · 2023: 4 · 2021: 5 · 2020: 3 · 2019: 4 · 2018: 3 · 2017: 5 · 2016: 2 · 2015: 2 · 2014: 4 · 2013: 4 · 2012: 2
- FWCI
- 7.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Pharmaceutical Design (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Keywords
- glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, GLP-1 analogues, type 2 diabetes, incretins, insulin secretion, cyclic AMP, antidiabetic drugs, N-terminal modification, amino acid substitutions, antidiabetic activity
- MeSH terms
- Animals, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glucagon, Humans, Hypoglycemic Agents, Peptide Fragments, Protein Precursors, Structure-Activity Relationship, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Structurally Modified Analogues of Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) As Future Antidiabetic Agents. https://app.cochat.ai/papers/10.2174/1381612043382774
- The paper
- Green, B., Gault, V., O'Harte, F., & Flatt, P. (2004). Structurally Modified Analogues of Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) As Future Antidiabetic Agents. Current Pharmaceutical Design. https://doi.org/10.2174/1381612043382774
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.